Articles related to ANTI-PSYCHOTICS

Schizophrenia is a chronic brain disorder characterized by hallucinations, delusions, and cognitive impairments, affecting up to 1 percent of the global population. Understanding its symptoms, causes, and treatment options is crucial for effective patient care.

Effective management of tardive dyskinesia requires early prevention with second-generation antipsychotics and the use of VMAT2 inhibitors like deutetrabenazine and valbenazine, which offer the highest quality evidence for reducing symptoms.

Research presented at the APA 2024 Annual Meeting sheds light on innovative treatments and the multifaceted burden of anxiety disorders, highlighting significant advances in managing GAD and related comorbidities.

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.

Metformin is emerging as a viable option for weight management in obese patients without diabetes, showing sustained weight loss effects and potential benefits in populations with prediabetes or undergoing antipsychotic treatment.

The Johns Hopkins Clozapine Consultation Clinic is addressing the critical underutilization of clozapine in treatment-resistant schizophrenia, providing essential support and education for healthcare providers in navigating its benefits and risks.